Jump to content

Hang Yin (scientist): Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Qr972500 (talk | contribs)
mNo edit summary
No edit summary
Line 28: Line 28:
|footnotes =
|footnotes =
}}
}}
'''Hang Hubert Yin''' (born 5 July 1976) is a chemistry professor at the Department of Chemistry and the BioFrontiers Institute,<ref>{{cite web|title=University of Colorado BioFrontiers Institute Webpage|url=http://cimb.colorado.edu}}</ref> [[University of Colorado Boulder]], a recipient of several young scientist awards for his research in [[chemical biology]] and [[drug discovery]].
'''Hang Hubert Yin''' (born 5 July 1976) is a chemistry professor involved in academic misconduct at the Department of Chemistry and the BioFrontiers Institute,<ref>{{cite web|title=University of Colorado BioFrontiers Institute Webpage|url=http://cimb.colorado.edu}}</ref> [[University of Colorado Boulder]], a recipient of several young scientist awards for his research in [[chemical biology]] and [[drug discovery]].


==Career==
==Career==

Revision as of 06:48, 20 November 2017

Hang Hubert Yin
Born5 July 1976 (1976-07-05) (age 48)
Alma materYale University
Scientific career
FieldsChemistry, Biology
InstitutionsUniversity of Colorado Boulder
Doctoral advisorAndrew D. Hamilton

Hang Hubert Yin (born 5 July 1976) is a chemistry professor involved in academic misconduct at the Department of Chemistry and the BioFrontiers Institute,[1] University of Colorado Boulder, a recipient of several young scientist awards for his research in chemical biology and drug discovery.

Career

Hang Hubert Yin was a pupil at the High School of Peking University. After studying for a bachelor's degree at the Peking University, he received his PhD from Yale University, New Haven in 2004 (supervisor: Professor Andrew D. Hamilton FRS) and then spent a post-doctoral period at the University of Pennsylvania School of Medicine under the supervision of Professor William DeGrado.[2] In 2007, he joined the faculty of the University of Colorado Boulder. His research interests lie at the interface of chemistry, biology, and engineering with particular focuses on structure-based drug design, cell signaling biochemistry, biotechnology development, and membrane protein simulations.[3]

Awards

Significant contributions

Yin's team showed that morphine causes inflammation by binding to the protein lymphocyte antigen 96, which, in turn, causes the protein to bind to an immune system receptor called Toll-like receptor 4 (TLR4).[11] The morphine-induced TLR4 activation attenuates pain suppression by opioid and enhances the development of opioid tolerance and addiction, drug abuse, and other negative side effects such as respiratory depression. The Yin group has developed drug candidates that can improve opioid-based pain management therapies.[12] On June 23, 2014, BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX) announced that it has in-licensed BL-1010, a novel compound for the treatment of neuropathic pain invented by Yin from the University of Colorado.[13] In 2015, Yin reported a new drug candidate that could change the way Parkinson's disease is treated.[14] The drug, called CU-CPT22, may help stop harmful inflammation in certain immune cells that is thought to cause Parkinson's.[15]

Notes

References

  1. ^ "University of Colorado BioFrontiers Institute Webpage".
  2. ^ "Yin AACR Bio". Archived from the original on 2012-06-25. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  3. ^ "Yin Research Group Website".
  4. ^ "ACS MEDI".
  5. ^ "Chinese-American Chemistry Professor Association website".
  6. ^ "SU2C news coverage".
  7. ^ "University of Colorado Boulder news coverage".
  8. ^ "Elion Award lecture" (PDF).
  9. ^ "University of Colorado Boulder news coverage".
  10. ^ "Howard Hughes Medical Institute news coverage".
  11. ^ Making morphine work better, Nature 2012, 484: 419
  12. ^ Drahl, C. Small Molecules Target Toll-Like Receptors, C&EN 2012, 90: 33
  13. ^ "BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain" (Press release). MarketWatch.
  14. ^ Making Aggregation Less Aggravating, Science 2015, 348: 769
  15. ^ "CU Parkinson's research could revolutionize treatment".